Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2026-01-03 @ 9:12 AM
Study NCT ID:
NCT04148092
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2020-05-29
First Post:
2019-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Sponsor:
Deciphera Pharmaceuticals, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2019-10-30
First Submit QC Date:
None
Study First Post Date:
2019-11-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-05-27
Last Update Post Date:
2020-05-29
Last Update Post Date Type:
ACTUAL